Can-Fite BioPharma Ltd.

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 TTM
Cash flows from operating activities:
Adjustments to reconcile net income to net cash provided by operating activities:
Net loss ($27.0m) ($5.0m) ($6.6m) ($9.6m) ($14.4m) ($12.6m) ($10.2m) ($7.6m) ($7.9m) ($9.8m)
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest ($8.4m) ($6.4m) ($6.6m) ($12.6m) ($14.4m) ($12.6m) ($10.2m) ($7.6m) ($7.9m) ($9.8m)
Depreciation, Depletion and Amortization $14k $12k $14k $14k $15k $7k $24k $24k
Depreciation of property, plant and equipment $71k $20k $14k $14k $12k $14k $14k $15k $7k $24k $24k
Share-based Payment Arrangement, Noncash Expense $535k $385k $355k $68k $263k $261k $362k $340k $340k
Adjustments For Share-Based Payments $322k $192k $535k $385k
Share-based Payment Arrangement, Expense $261k $362k $340k $340k
Nonoperating Income (Expense) ($618k) ($304k) $227k ($77k) $561k $250k $122k
Changes in operating assets and liabilities:
Increase (Decrease) in Accounts Receivable ($270k)
Increase (decrease) in other accounts payable ($631k) $22k $125k ($512k) ($279k) $574k ($130k) $169k $32k $133k
Decrease in deferred revenues $1.2m $146k ($401k) $1.4m ($810k) ($743k) ($349k) ($405k)
Change in prepaid expenses, and other current assets ($853k) $270k $2.7m $128k ($241k) $184k ($109k) $195k
Net Cash Provided by (Used in) Operating Activities ($34.3m)
($9.5m) +72.20%
($4.2m) +56.47%
($10.8m) -160.75%
($12.1m) -11.34%
($9.9m) +18.28%
($10.8m) -9.57%
($8.4m) +21.86%
($7.6m) +9.51%
($8.9m) -17.18%
($8.9m) 0.00%
Cash flows from investing activities:
Payments to Acquire Property, Plant, and Equipment ($40k) ($7k) ($33k) $3k $26k $11k $9k $2k $5k $2k ($2k)
Cash, Cash Equivalents, and Short-term Investments $8.9m $7.9m
Gain (Loss) on Investments $11k $162k
Net Cash Provided by (Used in) Investing Activities ($40k) ($30k) ($33k) ($253k) ($26k) ($14.5m) $9.5m $498k $1.5m ($2k) ($2k)
Cash flows from financing activities:
Proceeds from Issuance of Common Stock $2.2m $2.9m $9.6m
Dividends paid $3
Net Cash Provided by (Used in) Financing Activities $4.9m
$4.4m -10.40%
$10.2m +131.75%
$17.7m +73.93%
$20.5m +15.69%
$9.1m
$6.7m -26.61%
$9.6m +43.70%
$9.6m 0.00%
Increase (decrease) in cash and cash equivalents ($34.8m) ($5.5m) $110k ($918k) $5.6m ($3.9m) ($1.4m) $1.3m $547k $703k
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $5.6m ($3.9m) ($1.4m) $1.3m $547k $703k $5.5m
Cash and cash equivalents at the beginning of the year $66.0m $9.0m $3.5m $3.6m $2.7m $8.3m $4.4m $3.0m $4.8m $5.5m
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $4.8m $5.5m $5.5m
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents ($113k) $98k ($22k) $10k $10k
Additional Supplementary Disclosures
Additional Supplementary Disclosures
Supplemental disclosure of cash flow information:
Interest Paid, Excluding Capitalized Interest, Operating Activities $29k $23k $18k
Additional Financial Items
Adjustments For Increase Decrease In Trade Account Payable $816k ($293k) $644k $1.1m
General and Administrative Expense $2.7m $2.9m $3.2m $3.1m $3.0m $3.8m $3.1m $3.0m $3.0m $3.7m
Interest Expense Nonoperating ($291k) $284k
Operating Expenses $8.8m $10.4m
Payments Of Lease Liabilities Classified As Financing Activities $34k
Proceeds From Issuing Shares $4.5m $4.4m $10.2m
Revenue from Contract with Customer, Including Assessed Tax $743k
Reduction in the carrying amount of operating lease right of use asset $9k $55k $54k $94k $37k $42k
Changes in fair value of short-term investment $5k $644k $209k ($11k) ($162k) $229k ($11k) $14k $4k
Financial expenses (income), net ($2k) $23k ($34k) $113k ($222k) $90k $36k
Decrease in operating lease liability ($33k) ($8k) ($63k) ($62k) ($84k) ($32k) ($33k)
Increase (decrease) in trade payable $644k $1.1m ($1.6m) $393k ($58k) ($469k) $191k $543k
Maturity of short-term deposits, net $9.5m $500k $1.5m
Issuance of ordinary shares due to ATM, net of issuance costs $2.2m $2.9m
Issuance of ordinary shares and warrants, net of issuance costs $9.1m $4.5m $6.7m
Exchange differences on balances of cash and cash equivalents ($443k) ($814k) ($89k) $2k ($23k) $34k ($113k) $98k ($22k) $10k
Lease liabilities arising from obtaining right-of-use-assets $76k $29k $120k $62k $96k